Human immunodeficiency virus-infection induces major changes in high-density lipoprotein particle size distribution and composition: The effect of antiretroviral treatment and disease severity

Clinical Chemistry and Laboratory Medicine

Volumn 48, Issue 8, 2010, Pages 1147-1152

  Aragonès, Gerard ^a   Beltrán Debón, Raúl ^a   Rull, Anna ^a   Rodríguez Sanabria, Fernando ^a   Fernández Sender, Laura ^b   Camps, Jordi ^a   Joven, Jorge ^a   Alonso Villaverde, Carlos ^a,b  

^a INSTITUT D INVESTIGACIÓ SANITÀRIA PERE VIRGILI IISPV   (Spain)

^b HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

Author keywords

antiretroviral therapy; CD4+ T cell; HIV infection; lipoprotein; particle size

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CHOLESTEROL; EFAVIRENZ; HIGH DENSITY LIPOPROTEIN; LOPINAVIR PLUS RITONAVIR; ZIDOVUDINE;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GEL PERMEATION CHROMATOGRAPHY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION PROCEDURE; LIPOPROTEIN BLOOD LEVEL; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PARTICLE SIZE; PRIORITY JOURNAL;

ADULT; ANTI-HIV AGENTS; BENZOXAZINES; CD4-POSITIVE T-LYMPHOCYTES; CHROMATOGRAPHY, GEL; DISEASE PROGRESSION; FEMALE; HIV INFECTIONS; HUMANS; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; PARTICLE SIZE;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 77955436572     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2010.218     Document Type: Article

References (20)

1. Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955;34:1345-1353
2. Li Z, McNamara JR, Ordovas JM, Schaefer EJ. Analysis of highdensity lipoproteins by a modified gradient gel electrophoresis method. J Lipid Res 1994;35:1698-1711
3. Delalla OF, Elliot HA, Gofman JW. Ultracentrifugal studies of high-density serum lipoproteins in clinically healthy adults. Am J Physiol 1954;179:333-337
4. Gwynne JT. High density lipoprotein cholesterol levels as a marker of reverse cholesterol transport. Am J Cardiol 1989;64: 10-17
5. Mackness MI, Durrington PN, Mackness B. The role of paraoxonase 1 activity in cardiovascular disease: potential for therapeutic intervention. Am J Cardiovasc Drugs 2004;4:211-217
6. Vaisar T, Pennathur S, Green PS, Gharib SA, Hoofnagle AN, Cheung MC, et. al. Shotgun proteomics implicates protease inhibition and complement activation in the anti-inflammatory properties of HDL. J Clin Invest 2007;117:746-756
7. Van Lenten BJ, Wagner AC, Nayak DP, Hama S, Navab M, Fogelman AM. High-density lipoprotein loses its anti-inflammatory properties during acute influenza infection. Circulation 2001;103:2283-2288
8. Van Lenten BJ, Hama SY, de Beer FC, Stafforini DM, McIntyre TM, Prescott SM, et. al. Anti-inflammatory HDL becomes proinflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest 1995;96:2758-2767
9. Bernal E, Masiá M, Padilla S, Gutiérrez F. High-density lipoprotein cholesterol in HIV-infected patients: evidence for an association with HIV-1 viral load, antiretroviral therapy status, and regimen composition. AIDS Patient Care STDS 2008;22: 569-575
10. Rose H, Hoy J, Woolley I, Tchoua U, Bukrinsky M, Dart A, et. al. HIV infection and high density lipoprotein metabolism. Atherosclerosis 2008;199:79-86.
11. Rose H, Woolley I, Hoy J, Dart A, Bryant B, Mijch A, et. al. HIV infection and high-density lipoprotein: The effect of the disease vs the effect of treatment. Metabolism 2006;55:90-95
12. Alonso-Villaverde C, Coll B, Parra S, Montero M, Calvo N, Tous M, et. al. Atherosclerosis in patients infected with HIV is influenced by a mutant monocyte chemoattractant protein-1 allele. Circulation 2004;110:2204-2209
13. Matas C, Cabré M, La Ville A, Prats E, Joven J, Turner PR, et. al. Limitations of the Friedewald formula for estimating lowdensity lipoprotein cholesterol in alcoholics with liver disease. Clin Chem 1994;40:404-406
14. Usui S, Hara Y, Hosaki S, Okazaki M. A new on-line dual enzymatic method for simultaneous quantification of cholesterol and triglycerides in lipoproteins by HPLC. J Lipid Res 2002;43:805-814
15. Davidson WS, Silva RA, Chantepie S, Lagor WR, Chapman MJ, Kontush A. Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters: relevance to antioxidative function. Arterioscler Thromb Vasc Biol 2009;29:870-876
16. Arsenault BJ, Lemieux I, Després JP, Gagnon P, Wareham NJ, Stroes ES, et. al. HDL particle size and the risk of coronary heart disease in apparently healthy men and women: The EPICNorfolk prospective population study. Atherosclerosis 2009; 206:276-281
17. El Harchaoui K, Arsenault BJ, Franssen R, Després JP, Hovingh GK, Stroes ES, et. al. High-density lipoprotein particle size and concentration and coronary risk. Ann Intern Med 2009;150:84-93.
18. Asztalos BF, Roheim PS, Milani RL, Lefevre M, McNamara JR, Horvath KV, et. al. Distribution of ApoA-I-containing HDL subpopulations in patients with coronary heart disease. Arterioscler Thromb Vasc Biol 2000;20:2670-2676
19. Parra S, Coll B, Aragonès G, Marsillach J, Beltrán R, Rull A, et. al. Nonconcordance between subclinical atherosclerosis and the calculated Framingham risk score in HIV-infected patients: relationships with serum markers of oxidation and inflammation. HIV Medicine 2009 win pressx.
20. Parra S, Alonso-Villaverde C, Coll B, Ferré N, Marsillach J, Aragonès G, et. al. Serum paraoxonase-1 activity and concentration are influenced by human immunodeficiency virus infection. Atherosclerosis 2007;194:175-181